Ivonescimab Beats Pembrolizumab in NSCLC Survival Study
Event summary
- Ivonescimab monotherapy demonstrated statistically significant overall survival (OS) benefit compared to pembrolizumab monotherapy in PD-L1-positive advanced NSCLC in the HARMONi-2 study.
- The study was conducted by Akeso in China, with results scheduled for presentation at an upcoming medical conference.
- Ivonescimab is approved in China but remains investigational in Summit’s license territories, including the U.S. and Europe.
- Summit has multiple Phase III trials ongoing for ivonescimab in various cancer indications.
The big picture
Summit Therapeutics’ ivonescimab is emerging as a potential disruptor in the PD-1 inhibitor space, with its unique bispecific antibody design targeting both PD-1 and VEGF. The positive OS data from the HARMONi-2 study reinforces its competitive edge, particularly in NSCLC. However, Summit must navigate regulatory hurdles outside China to fully capitalize on this breakthrough.
What we're watching
- Regulatory Pathways
- Whether ivonescimab can secure approvals in the U.S. and Europe, given its success in China.
- Clinical Pipeline
- The pace at which Summit can advance its global Phase III trials for ivonescimab in other cancer indications.
- Market Competition
- How ivonescimab’s differentiated design will position it against established PD-1 inhibitors like pembrolizumab.
Related topics